Clinical Trials Logo

Wiskott-Aldrich Syndrome clinical trials

View clinical trials related to Wiskott-Aldrich Syndrome.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT03198195 Enrolling by invitation - Clinical trials for Wiskott-Aldrich Syndrome

Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome

Start date: March 10, 2015
Phase: N/A
Study type: Observational [Patient Registry]

A protocol named as "CIP-2015" for patients with Wiskott-Aldrich Syndrome may reduce the rate of GvHD. The details of the protocal followed with: 1. Conditioning regimen Busulfan 16 mg/kg in total, Fludarabine 160 mg/m2 in total. 2. GvHD Prophylaxis: Rabbit antihuman thymocyte globulin 7.5 mg/kg post-transplant cyclophosphamide (CY) (50 mg/kg.d on days +3 and +4) Cyclosporine or tacrolimus, mycophenolate mofetil, on days +5

NCT ID: NCT01852370 Enrolling by invitation - Clinical trials for Wiskott-Aldrich Syndrome

Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases

BOLT+BMT
Start date: June 20, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether bilateral orthotopic lung transplantation (BOLT) followed by cadaveric partially-matched hematopoietic stem cell transplantation (HSCT) is safe and effective for patients aged 5-45 years with primary immunodeficiency (PID) and end-stage lung disease.